Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRC

Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Read the whole article on Physorg

More from Physorg